DSM Signs Capsules Contract With QRxPharma
DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., recently announced the signing of a manufacturing and supply agreement with QRxPharma, Inc., based in
The agreement covers the production of MoxDuo Capsules, an immediate-release Dual Opioid pain therapy composed of a patented 3:2 fixed ratio combination of morphine and oxycodone by DSM, who will supply commercial volumes upon marketing approval. DSM operates a 1.5-million-sq-ft finished dosage facility in
“We are honored to be working with QRxPharma for the supply of this product,” said Hans Engels, President, DSM Pharmaceuticals, Inc. “Combining the expertise of QRx in developing innovative medicines with DSM’s strength in Good Manufacturing Practices (GMP), enforced by the US FDA, and supply chain management will provide a superior solution for patients.”
QRxPharma, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervoussystem (CNS) disorders.
“We have had a very productive relationship with DSM over the years as we evolved MoxDuo Capsules through to New Drug Application (NDA) filing, and we are now looking forward to launching our product into the acute pain marketplace in the US in 2012 with the manufacturing support of DSM,” added Dr. John Holaday, Managing Director and CEO of QRxPharma.
Total Page Views: 1046
